Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07563829 · ClinicalTrials.gov registry record · Phase 1
NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies
A Phase 1 study, sponsored by NextPoint Therapeutics.
- Not yet
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
NCT07563829: Clinical Trial Phase 1 study, sponsored by NextPoint Therapeutics.
NCT07563829 is a Phase 1 study that has not yet begun recruiting, run by NextPoint Therapeutics. The registered enrollment target is 81 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07563829, a Phase 1 study, has not yet begun recruiting, sponsored by NextPoint Therapeutics.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
Study Summary
NPX372 is an antibody drug (protein drug) that blocks a specific protein which is found to be increased on the surface of cancer cells called B7-H7 and, at the same time, binds to immune cells (T cells) through a receptor called CD3. The effect of this binding is to activate T cells to kill cancer cells with B7-H7. In this research study we are: * Evaluating the safety and possible effectiveness of NPX372. * Identifying a safe and tolerable dose or doses for further study. Participants who are treated will receive an intravenous (IV) infusion of NPX372 if their disease has not progressed, and be closely monitored by the treating physicians.
Primary Outcome
Number of participants with DLT
Interventions
- DRUG NPX372
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2027-07-01 |
| Phase | Phase 1 |
What is known before NCT07563829 opens enrollment
NCT07563829 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% higher).
The record links to 0 conditions, and to 1 intervention - of which NPX372 is the first listed.
NCT07563829 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07563829 about?
NCT07563829 is a clinical study titled "NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies". NPX372 is an antibody drug (protein drug) that blocks a specific protein which is found to be increased on the surface of cancer cells called B7-H7 and, at the same time, binds to immune cells (T cells) through a receptor called CD3. The effect of this binding is to activate T cells to kill cancer c...
What is the current status of trial NCT07563829?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2026-04-01. Estimated completion is 2027-07-01.
What interventions are being tested in trial NCT07563829?
The interventions under investigation include: NPX372 (DRUG).
Who is sponsoring clinical trial NCT07563829?
This trial is sponsored by NextPoint Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07563829's enrollment target sits among peer trials
81 671st of 2000 higher than 1,329 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI